Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells.

Audrey Grain,Jocelyn Ollier,Thierry Guillaume,Patrice Chevallier,Baptiste Le Calvez,Marion Eveillard,Béatrice Clémenceau

Biomedicines（2023）

引用 0|浏览5

暂无评分

摘要

CD19 relapses of ALL remain sensitive to cell lysis mediated by T-cell effectors. In case of ALL relapses after immunotherapy, a large immunophenotype will make new therapies possible for controlling such high risk ALL.

查看译文

关键词

CAR-T cells,acute lymphoblastic leukaemia,immunotherapy,relapse

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要